Q-omics provides the consensus-scored PARD3B profile across patient tissues and cancer cell-line models. PARD3B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PARD3B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PARD3B protein abundance shows 25,164 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where PARD3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARD3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARD3B survival associations across molecular data types. PARD3B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARD3B RNA expression–survival associations across cancer types. High PARD3B expression shows favorable associations in KIRC, LUAD, UVM, BRCA, MESO and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PARD3B RNA expression.
This table summarizes PARD3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARD3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARD3B shows lower tumor expression in KIRC, KICH, BLCA, THCA and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher PARD3B RNA expression in normal versus tumor tissue (log2 FC = −1.066, t-test p < 0.001).
This table shows molecular features associated with PARD3B in patient tissues and cancer cell lines. In patient samples, PARD3B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PARD3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
